Dr. Syed Bukhari
Dr. Syed Bukhari United States
Title: Transthyretin Cardiac Amyloidosis is a Predictor of Thromboembolism in Atrial Fibrillation, Independent of CHA2DS2Vasc Score
Biography
Biography: Dr. Syed Bukhari
Abstract
Transthyretin cardiac amyloidosis (ATTR-CA) results from the myocardial interstitial deposition of misfolded transthyretin fibrils, and is non-invasively diagnosed with the help of Tc-99m pyrophosphate (PYP) scintigraphy. The amyloid infiltration is thought to increase the risk of intracardiac blood stagnation and hence intracardiac thrombosis. However, the impact of ATTR-CA on thromboembolic risk in patients with atrial fibrillation (AF) is unknown.
Objective:
Our study was aimed to investigate the prevalence of AF as well the incidence of thromboembolism in the patient population with ATTR-CA.
Methods:
We studied patients who underwent Tc-99m pyrophosphate scintigraphy (PYP) between 6/2015 and 6/2019. Those with positive Tc-99m PYP and a negative serum studies for light-chain amyloidosis were diagnosed with ATTR-CA. We compared the prevalence of AF in patients with and without ATTR-CA and the incidence of thromboembolism (stroke, TIA or systemic embolism) in AF patients with ATTR-CA (AF-ATTR) and without (AF-controls).